Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $549.0K | $467.0K | $436.0K | $273.0K | $531.0K | $10.1M | $91.9M | $91.7M |
| Cost of revenue | $176.0K | $516.0K | $607.0K | $455.0K | $1.0M | $5.3M | $77.4M | $79.9M |
| Gross profit | $373.0K | −$49.0K | −$171.0K | −$182.0K | −$503.0K | $4.8M | $14.5M | $11.8M |
| Gross margin | 67.9% | -10.5% | -39.2% | -66.7% | -94.7% | 47.5% | 15.7% | 12.9% |
| R&D | $3.7M | $2.2M | $1.8M | $609.0K | $997.0K | $1.0M | $4.9M | $5.9M |
| Operating income | −$9.1M | −$6.1M | −$6.7M | −$14.4M | −$7.4M | −$8.2M | −$13.8M | −$23.3M |
| EBITDA | −$9.0M | −$6.0M | −$6.8M | −$14.3M | −$7.2M | $4.8M | −$12.0M | −$27.3M |
| Net income | −$9.0M | −$2.5M | −$6.6M | −$14.2M | −$6.8M | $4.0M | −$10.2M | −$16.0M |
| Net margin | -1640.6% | -545.0% | -1513.3% | -5193.4% | -1290.0% | 40.0% | -11.1% | -17.5% |
| EPS (diluted) | -786.00 | -69.88 | -47.14 | -2.72 | -0.77 | 0.13 | -6.28 | -9.50 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds MDGS.
No tracked institution reports a position in MDGS as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-11-14 | 1-for-15reverse |
| 2018-07-16 | 1-for-4reverse |
| 2017-03-15 | 1-for-10reverse |
| 2008-03-24 | 1-for-2reverse |
No one on the platform has traded MDGS yet.
| $5M |
| — |
| NBRVFNabriva Therapeutics plc | $0.00 | +0.00% | $323 | — |
| NUVOHoldco Nuvo Group D.G Ltd. Ordinary Shares | $0.17 | +100.00% | $6M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× sales vs its 0.2× historical median P/S.
Fair value ≈ $25.14 · price $2.36 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.